ERBB2 and cancer: The consensus in our institution regarding adjuvant radiation and chemotherapy for these patients is ill-defined, owing to a lack of HER2 status testing and consequent treatment; absence of national recommendations, guidelines, or national follow-up programs for cancer patients; and, above all, very poor patient compliance to treatment or to the limited follow-up services available.